Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment (INTEREST)

12. listopadu 2026 aktualizováno: University Hospital, Brest

Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.

Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.

This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.

Přehled studie

Postavení

Zatím nenabíráme

Intervence / Léčba

Detailní popis

Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.

Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.

The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.

The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.

The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.

Typ studie

Intervenční

Zápis (Odhadovaný)

50

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
  • Stable cytoreductive therapy for at least 6 months
  • Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
  • Adult patient capable of providing informed consent

Exclusion Criteria:

  • Recurrent or poorly controlled infections
  • Thrombocytopenia < 100 G/L
  • Neutropenia < 1 G/L
  • Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
  • Concomitant immunosuppressive therapy
  • Refusal to participate
  • Patient under legal protection (guardianship, curatorship, etc.)
  • Patients unable to consent.
  • Positive urine pregnancy test at screening / pregnant or breastfeeding women.
  • Lack of understanding of questionnaires or inability to follow up.
  • Women of childbearing potential unwilling to use a highly effective contraceptive methods

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Anakinra + cytoreductive therapy

Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence.

Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary.

Žádný zásah: Cytoreductive therapy alone

Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in serum calprotectin levels
Časové okno: Baseline and Month 3

Calprotectin levels are measured on serum samples by centralized analysis (µg/mL)

Baseline and Month 3

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Improvement (yes/no) of the response status between baseline and month 3.
Časové okno: Month 3

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 3
Improvement (yes/no) of the response status between baseline and month 6.
Časové okno: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Improvement (yes/no) of the response status between month 3 and month 6.
Časové okno: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Hemoglobin count
Časové okno: Baseline

Measurement of Hemoglobin in g/dL

Baseline
Hematocrit count
Časové okno: Baseline

Measurement of Hematocrit in %

Baseline
White blood cell count
Časové okno: Baseline

Measurement of WBC in G/L

Baseline
Platelet cell count
Časové okno: Baseline

Measurement of Platelets in G/L

Baseline
Hemoglobin count
Časové okno: Month 3

Measurement of Hemoglobin in g/dL

Month 3
Hematocrit count
Časové okno: Month 3

Measurement of Hematocrit in %

Month 3
White blood cell count
Časové okno: Month 3

Measurement of WBC in G/L

Month 3
Platelet cell count
Časové okno: Month 3

Measurement of Platelets in G/L

Month 3
Hemoglobin count
Časové okno: Month 6

Measurement of Hemoglobin in g/dL

Month 6
Hematocrit count
Časové okno: Month 6

Measurement of Hematocrit in %

Month 6
White blood cell count
Časové okno: Month 6

Measurement of WBC in G/L

Month 6
Platelet cell count
Časové okno: Month 6

Measurement of Platelets in G/L

Month 6
Treatment-related adverse event for experimental group
Časové okno: Month 1

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 1
Treatment-related adverse event for experimental group
Časové okno: Month 3

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 3
Treatment-related adverse event for experimental group
Časové okno: Month 6

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 6
Adherence to treatment regimen for experimental group
Časové okno: Month 1

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation.

Month 1
Adherence to treatment regimen for experimental group
Časové okno: Month 2

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation

Month 2
Adherence to treatment regimen for experimental group
Časové okno: Month 3

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation.

Month 3
QLQ-C30 Summary Score
Časové okno: Baseline

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Baseline
QLQ-C30 Summary Score
Časové okno: Month 3

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 3
QLQ-C30 Summary Score
Časové okno: Month 6

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 6
Global health status / QoL score
Časové okno: Baseline

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Baseline
Global health status / QoL score
Časové okno: Month 3

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 3
Global health status / QoL score
Časové okno: Month 6

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 6
Patient-reported symptom severity over the previous 4 weeks for pruritus
Časové okno: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever
Časové okno: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Časové okno: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for pruritus
Časové okno: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever
Časové okno: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Časové okno: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for pruritus
Časové okno: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever
Časové okno: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Časové okno: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Inflammatory biological profile
Časové okno: Baseline

Measurement of IL-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Časové okno: Month 3

Measurement of IL-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Časové okno: Month 6

Measurement of IL-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Časové okno: Baseline

Measurement of IL-6 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Časové okno: Month 3

Measurement of IL-6 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Časové okno: Month 6

Measurement of IL-6 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Časové okno: Baseline

Measurement of IL-8 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Časové okno: Month 3

Measurement of IL-8 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Časové okno: Month 6

Measurement of IL-8 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Časové okno: Baseline

Measurement of MIP-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Časové okno: Month 3

Measurement of MIP-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Časové okno: Month 6

Measurement of MIP-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Časové okno: Baseline

Measurement of TNF-α cytokines in pg/mL.

Baseline
Inflammatory biological profile
Časové okno: Month 3

Measurement of TNF-α cytokines in pg/mL.

Month 3
Inflammatory biological profile
Časové okno: Month 6

Measurement of TNF-α cytokines in pg/mL.

Month 6
Allele burden of the driver mutation
Časové okno: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Baseline
Allele burden of the driver mutation
Časové okno: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 3
Allele burden of the driver mutation
Časové okno: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 6
Allele burden of the driver mutation
Časové okno: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Baseline
Allele burden of the driver mutation
Časové okno: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 3
Allele burden of the driver mutation
Časové okno: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 6
Allele burden of the driver mutation
Časové okno: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Baseline
Allele burden of the driver mutation
Časové okno: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 3
Allele burden of the driver mutation
Časové okno: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 6
Fibrosis markers
Časové okno: Baseline

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Baseline
Fibrosis markers
Časové okno: Month 3

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 3
Fibrosis markers
Časové okno: Month 6

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 6

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. února 2027

Primární dokončení (Odhadovaný)

1. srpna 2028

Dokončení studie (Odhadovaný)

1. srpna 2028

Termíny zápisu do studia

První předloženo

3. července 2026

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit